Rhythm Pharmaceuticals, Inc. (RYTM)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$101.06-0.73%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Intact: The reason to own it still holds.
Rhythm is growing IMCIVREE revenue from $130M in 2024 to $194M in 2025. The company expanded market authorization for IMCIVREE to treat more obesity types. Operating expenses are guided to stay between $385M and $415M in 2026. Recent positive trial data and approvals support future growth.
Rhythm remains loss-making with negative EPS expected through 2027. Revenue growth depends on successful market expansion and regulatory approvals. Operating costs near $400M could pressure profitability if sales slow.
The price is about 5% above our fair value near $108, reflecting roughly 85% revenue growth expected by analysts. Our fair value is 24% below the Street median, indicating some optimism priced in that we view as aggressive.
Breaks if: IMCIVREE revenue falls below $130 million in 2025
Breaks if: Failure to maintain or expand IMCIVREE market authorization by end 2026
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. RYTM is currently loss-making but is focused on expanding its product offerings and advancing its clinical pipeline, which adds a layer of uncertainty to the thesis.
The market appears to be pricing in a justified valuation with a low expectations gap. RYTM is trading at a premium compared to its peers, indicating that investors may have high hopes for its future performance despite current losses.
Management is on track with expanding the market for IMCIVREE and has shown mixed progress in advancing its clinical pipeline. However, the company operates in a high-miss-rate industry, which adds risk to its near-term performance.
The long-term thesis hinges on the company's ability to maintain momentum in its product launches and clinical developments. Additionally, broader sector performance and economic conditions, such as job growth, will significantly impact RYTM's trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats identified that could weaken the thesis.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Obtain regulatory approvals and launch IMCIVREE for acquired hypothalamic obesity in multiple regions including U.S., Europe, and Japan.
Breaks if: Operating expenses exceed $415 million in FY26
Control Non-GAAP operating expenses for 2026 within the guided range of $385 million to $415 million.
Over the next 1 to 3 years, RYTM's success will depend on its execution of strategic priorities and external market conditions. Not investment advice.